In 1952, hundreds of thousands of U.S. troops coming home from the Korean Peninsula were given primaquine to prevent the spread of malaria. And it worked.
But military doctors soon began noticing that some soldiers who’d received the medication became jaundiced and anemic. The reasons weren’t clear until 1956 when a connection between the side effects and the drug was made; only people with a common hereditary genetic mutation suffered the drug’s ill effects.
Primaquine was an early lesson in the value of developing therapies uniquely matched to the patient — something that will soon be happening in Pittsburgh on a much bigger scale in the city as part of a larger shift to personalized medicine.
“This kind of science is mind blowing,” said Mario Miele, senior vice president of for-profit ElevateBio, the Waltham, Massachusetts-based biotech and first tenant in the University of Pittsburgh’s BioForge biomanufacturing facility at Hazelwood Green. “You can feel the energy in Pittsburgh. This is truly personalized medicine.”
Mr. Miele was among three ElevateBio executives to address the BioBreakfast networking group meeting Tuesday in South Oakland.
ElevateBio, a 7-year-old venture capital-backed startup, will occupy about 70,000 square feet of space at the 185,000-square-foot BioForge and is projected to employ at least 170 people when it becomes fully operational by early 2027.
Read More
BioForge is a $250 million lab and manufacturing facility nearing completion on a site where industrial coke was once made for more than a century.
The project received a $100 million grant from the Richard King Mellon Foundation and an $860,000 state grant.
The ElevateBio facility will be equipped with bioreactors, cryo-freezers and 10 clean rooms, where medicines — uniquely tailored to the individual patient — will be produced under contract with pharma companies, university researchers and startup companies. The raw material for these autologous medicines will be drawn from cells and tissue drawn from the patient, souped up in the ElevateBio’s Hazelwood lab, then administered back to the patient.
Here’s an example of a cell-based gene therapy.
Last year, the Food and Drug Administration approved the first cell-based gene therapies for the treatment of sickle cell disease, which affects about 100,000 people in the U.S. Both products are made from the patients’ own blood stem cells, which are modified in the lab and returned to the patient in an infusion.
In Pittsburgh, the turnaround time for these therapies could range from days to a week, Mr. Miele said.
ElevateBio’s Pittsburgh office will also make therapies with its partners from blood and other tissue drawn from healthy people. The patient’s stem cells will be treated in the lab, then stored as an “off the shelf” allogeneic medicine for when they are needed urgently.
Psoriasis, a type of childhood leukemia, and insulin resistance are among the diseases that have been successfully treated with allogeneic medicines.
“We want to push a button at the beginning and get a finished product at the end,” said Jeff Cram, senior director, cellular process development at ElevateBio.
The field of gene editing nearly came to a standstill in the late 1990s when viruses used in the process caused secondary, sometimes dangerous complications, halting some research projects for safety reasons, said Rita Bottino. She heads the islet transplant program at Uptown-based Imagine Pharma, but is not involved with ElevateBio.
Since then, safer, more effective techniques have been developed.
“Overall, what we have learned in the last 20 years has absolutely improved the safety of gene therapy,” she said.
“The principle was not wrong; it’s the editing of the genes that has changed. The science and intense work that was done to improve the safety of gene therapy is paying off now.”






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.